We observed lower percentages of γδT cells expressing CD62L in the group of patients with stable colitis (26.5 ± 6.2; Group A) compared to colitis exacerbation (42.4 ± 3.6; Group B) and the control group (44.4 ± 5.0; Group C), (Group A vs. B and C; p < 0.01). The gene discussed is SELL; the disease is colitis.